Somatic genetic alterations in breast cancer;Genetique somatique du cancer du sein

Bulletin du Cancer

Volumn 84, Issue 1, 1997, Pages 83-96

  Bièche, Ivan ^a,b   Lidereau, Rosette ^a  

^a CENTRE RENÉ HUGUENIN   (France)

^b FACULTÉ DES SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES   (France)

Author keywords

clinical applications; proto oncogenes; sporadic cancers; tumor suppressor genes

Indexed keywords

BREAST CANCER; FEMALE; HUMAN; PROTO ONCOGENE; REVIEW; TUMOR SUPPRESSOR GENE; APOPTOSIS; BREAST TUMOR; CELL CYCLE; CELL TRANSFORMATION; DRUG RESISTANCE; GENE AMPLIFICATION; GENETIC PROCEDURES; GENETICS; PROGNOSIS; SIGNAL TRANSDUCTION;

CELL ADHESION MOLECULE; GROWTH PROMOTOR;

APOPTOSIS; BREAST NEOPLASMS; CELL ADHESION MOLECULES; CELL CYCLE; CELL TRANSFORMATION, NEOPLASTIC; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE AMPLIFICATION; GENES, TUMOR SUPPRESSOR; GENETIC TECHNIQUES; GROWTH SUBSTANCES; HUMANS; PROGNOSIS; PROTO-ONCOGENES; SIGNAL TRANSDUCTION;

EID: 0030626999     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug J, Akslen L, Lonning P. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Med 1996; 2: 811-4.
2. Adnane J, Gaudray P, Dionne CA, Crumley G, Jaye M, Schlessinger J, Jeanteur P, Birnbaum D, Theillet C. BEK and FLG, two receptors tc members of the FGF family, are amplified in subsets of human breast cancers. Oncogene 1991; 6: 659-63.
3. Aldaz C, Chen T, Sahin A, Cunningham J, Bondy M. Comparative allelotype of in situ and invasive human breast cancer: high frequency of microsatellite instability in lobular breast carcinomas. Cancer Res 1995; 55: 3076-981.
4. Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW, Osborne CK, Tormey DC, McGuire WL. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 1992; 23: 974-9.
5. HER2 monoclonal antibody in patients with HER2/neu overexpressing metastatic breast cancer. J Clin Oncol 1996; 14: 737-44.
6. Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nature Med 1995; 1: 1029-34.
7. Berns EMJJ, Klijn JGM, Van Staveren IL, Portengen H, Foekens JA. Sporadic amplification of the insulin-like growth factor 1 receptor gene in human breast tumors. Cancer Res 1992a; 52: 1036-9.
8. Berns EMJJ, Klijn JGM, van Putten WLJ, van Staveren IL, Portengen H, Foekens JA. C-myc amplification is a better pronostic factor than HER2/neu amplification in primary breast cancer. Cancer Res 1992b; 52: 1107-13.
9. Berx G, Cleton-Jansen AM, Nollet F, de Leeuw WJF, van de Vilver MJ, Cornelisse C, van Roy F. E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J 1995; 14: 6107-15.
10. Bièche I, Champème MH, Matifas F, Hacène K, Callahan R, Lidereau R. Loss of heterozygosity on chromosome 7q and aggressive primary breast cancer. Lancet 1992; 339: 139-43.
11. Bièche I, Champème MH, Lidereau R. A tumor suppressor gene on chromosome 1p32-pter controls the amplification of MYC family genes in breast cancer. Cancer Res 1994; 54: 4274-6.
12. Bièche I, Champème MH, Lidereau R. Loss and gain of distinct regions of chromosome 1q in primary breast cancer. Clin Cancer Res 1995; 1: 123-7.
13. Bièche I, Tomasetto C, Régnier C, Moog-Lutz C, Rio M, Lidereau R. Two distinct amplified regions at 17q11-q21 involved in human primary breast cancer. Cancer Res 1996; 56: 3886-90.
14. Blaszyk H, Vaughn CB, Hartmann A, McGovern RM, Schroeder JJ, Cunningham J, Schaid D, Sommer SS, Kovach JS. Novel pattern of p53 gene mutations in an American Black cohort with high mortality from breast cancer. Lancet 1994; 343: 1195-7.
15. Borresen A, Andersen T, Eyfjörd J, Cornelis R, Thorlacius S, Borg A, Johansson U, Theillet C, Scherneck S, Hartman S, Cornelisse C, Hovig E, Devilee P. TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosom Cancer 1995; 14: 71-5.
16. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682-9.
17. Brinkmann U, Gallo M, Polymeropoulos M, Pastan I. The human CAS (cellular apoptosis susceptibility) gene mapping on chromosome 20q13 is amplified in BT474 breast cancer cells and part of aberrant chromosomes in breast and colon cancer cell lines. Genome Res 1996; 6: 187-94.
18. Canzian F, Salovaara R, Hemminki A, Kristo P, Chadwick R, Aaltonen L, de la Chapelle A. Semi-automated assessment of loss of heterozygosity and replication error in tumors. Cancer Res 1996; 56: 3331-7.
19. Casey G, Lo-Hsueh M, Lopez ME, Vogelstein B, Stanbridge EJ. Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene. Oncogene 1991; 6: 1791-7.
20. Clark GM, McGuire WL. Follow-up of HER-2/neu amplification in primary breast cancer. Cancer Res 1991; 51: 944-8.
21. Cotton RGH. Detection of unknown mutations in DNA. Am J Hum Genet 1996; 59: 289-91.
22. Counts J, Goodman J. Alterations in DNA methylation may play a variety of roles in carcinogenesis. Cell 1995; 83: 13-5.
23. Daidone M, Silvistrini R, Luisi A, Mastore M, Benini E, Veneroni S, Brambilla C, Ferrari L, Greco M, Andreola S, Veronesi U. Changes in biological markers after primary chemotherapy for breast cancers. Int J Cancer 1995; 61: 301-5.
24. Dalbagni G, Presti J, Reuter V, Fair WR, Cordon-Cardo C. Genetic alterations in bladder cancer. Lancer 1993; 342: 469-71.
25. Elledge R, Gray R, Mansour E, Yu Y, Clark G, Ravdin P, Osborne C, Gilchrist K, Davidson N, Robert N, Tormey N, Allred D. Accumulation of p53 protein as a possible predictor of response to adjuvant combination chemotherapy with cyclophosphamide, methotrexate, fluorouracil, and prednisone for breast cancer. J Natl Cancer Inst 1995; 87: 1254-6.
26. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-67.
27. Gasparini G, Pozza F, Harris AL. Evaluating the potential usefulness of new pronostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 1993; 85: 1206-19.
28. Graff J, Herman J, Lapidus R, Chopra H, Xu R, Jarrard D, Isaacs W, Pitha P, Davidson N, Baylin S. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res 1995; 55: 5195-9.
29. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855-78.
30. Gruis NA, Abeln ECA, Bardoel AFJ, Devilee P, Fronts RR, Cornelisse CJ. PCR-based microsatellite polymorphisms in the detection of loss of heterozygosity in fresh and archival tumour tissue. Br J Cancer 1993; 68: 308-13.
31. Guan XY, Xu J, Anzich S, Zhang H, Trent J, Meltzer P. Hybrid selection of transcribed sequences from microdissected DNA: isolation of genes within an amplified region at 20q11-q13.2 in breast cancer. Cancer Res 1996; 56: 3446-50.
32. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, Styles J, Rudenstam CM, Golouh R, Reed R, Martinez-Tello F, Tiltman A, Torhorst J, Grigolato P, Bettelheim R, Neville AM, Burki K, Castiglione M, Collins J, Lindtner J, Senn HJ. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 1992; 10: 1049-56.
33. Hankins G, Souza AD, Bentley R, Patel M, Marks J, Iglehart J, Jirtle R. M6P/IGF2 receptor: a candidate breast tumor suppressor gene. Oncogene 1996; 12: 2003-9.
34. Herman J, Merlo A, Mao L, Lapidus R, Issa J, Davidson N, Sidransky D, Baylin S. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995; 55: 4525-30.
35. Hiyama E, Gollahon L, Kataoka T, Kuroi K, Yokoyama T, Gazdar A, Hiyama K, Piatyszek M, Shay J. Telomerase activity in human breast tumors. J Natl Cancer Inst 1996; 88: 116-22.
36. Holt JT, Thompson ME, Szabo C, Robinson-Benion C, Arteaga CL, King MC, Jensen RA. Growth retardation and tumour inhibition by BRCA1. Nature Genet 1996; 12: 298-302.
37. Karlseder J, Zeillinger R, Schneeberger C, Czerwenka K, Speiser P, Kubista E, Birnbaum D, Gaudray P, Theillet C. Patterns of DNA amplification at band q13 of chromosome 11 in human breast cancer. Genes Chrom Cancer 1994; 9: 42-8.
38. Karunagaran D, Tzahar E, Beerli R, Chen X, Graus-Porta D, Ratzkin B, Seger R, Hynes N, Yarden Y. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 1996; 15: 254-64.
39. Keyomarsi K, O'Leary N, Molnar G, Lees E, Fingert HJ, Pardee AB. Cyclin E, a potential prognostic marker for breast cancer. Cancer Res 1994; 54: 380-5.
40. Knudson AG. Antioncogenes and human cancer. Proc Natl Acad Sci USA 1993; 90: 10914-21.
41. Krontiris TG, Devlin B, Karp DD, Robert NJ, Risch N. An association between the risk of cancer and mutations in the HRAS1 minisatellite locus. N Engl J Med 1993; 329: 517-23.
42. Lapidus R, Ferguson A, Ottaviano Y, Parl F, Smith H, Weitzman S, Baylin S, Issa J, Davidson N. Methylation of estrogen and progesterone receptor gene 5′ CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clin Cancer Res 1996; 2: 805-10.
43. Leitzel K, Teramoto Y, Konrad K, Chinchili V, Volas G, Grossberg H, Harvey H, Demers L, Lipton A. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 1995; 13: 1129-35.
44. Leone A, Flatow U, VanHoutte K, Steeg PS. Transfection of human nm23-H1 into the human MDA-MB-435 breast carcinoma cell line: effects on tumor metastatic potentiel, colonization and enzymatic activity. Oncogene 1993; 8: 2325-33.
45. Lindblom A, Rotstein S, Stoog L, Nordenskjöld M, Larson C. Deletions on chromosome 16 in primary familial breast carcinomas are associated with development of distant metastases. Cancer Res 1993; 53: 3707-11.
46. Lippman ME. The development of biological therapies for breast cancer. Science 1993; 259: 631-2.
47. Lönn U, Lönn S, Nilsson B., Stenkvist B. Higher frequency of gene amplification in breast cancer patients who received adjuvant chemotherapy. Cancer 1996; 77: 107-12.
48. Lothe RA, Peltomäki P, Meling GI, Aaltonen LA, Nyström-Lahti M, Pylkkänen L, Heimdal K, Andersen TI, Moller P, Rognum TO, Fossa SD, Haldorsen T, Langmark F, Brogger A, de la Chapelle A, Borresen AL. Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res 1993; 53: 5849-52.
49. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-67.
50. Makos-Wales MM, Biel M, Deiry WE, Nelkin B, Issa J, Cavenee W, Kuerbitz S, Baylin S. p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nature Med 1995; 1: 570-7.
51. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, Friend SH. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science 1990; 250: 1233-8.
52. Marchetti A, Buttitta F, Pellegrini S, Campani D, Diella F, Cecchetti D, Callahan R, Bistocchi M. p53 mutations and histological type of invasive breast carcinoma. Cancer Res 1993; 53: 4665-9.
53. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan R, Zborowska E, Kinzler K, Vogelstein B, Brattain M, Willson J. Inactivation of the type II TGF-b receptor in colon cancer cells with microsatellite instability. Science 1995; 268: 1336-8.
54. Mulahy HE, Croke DT, Farthing MJG. Cancer and mutant DNA in blood. Lancet 1996; 348: 628.
55. Muleris M, Almeida A, Gerbault-Seureau M, Malfroy B, Dutrillaux B. Detection of DNA amplification in 17 primary breast carcinomas with homogeneously staining regions by a modified comparative genomic hybridization technique. Genes Chrom Cancer 1994; 10: 160-70.
56. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, Henderson IC. C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994; 330: 1260-6.
57. Negrini M, Monaco C, Vorechovsky I, Ohta M, Druck T, Baffa R, Huebner K, Croce C. The FHIT gene at 3p14.2 is abnormal in breast carcinomas. Cancer Res 1996; 56: 3173-9.
58. Özçelik H, Mousses S, Andrulis I. Low levels of expression of an inhibitor of cyclin-dependent kinases (CIP1/WAF1) in primary breast carcinomas with p53 mutations. Clin Cancer Res 1995; 1: 907-12.
59. Pandey P, Kharbanda S, Kufe D. Association of the DF3/MUC1 breast cancer antigen with Grb2 and the Sos/Ras exchange protein. Cancer Res 1995; 55: 4000-3.
60. Park J, Hong K, Carter P, Asgari H, Guo L, Keller G, Wirth C, Shalaby R, Kotts C, Wood W, Papahadjopoulos D, Benz C. Development of anti-p185 HER2 immunoliposomes for cancer therapy. Proc Natl Acad Sci USA 1995; 92: 1327-31.
61. Peyrat J, Bonneterre J, Lubin R, Vanlemmens L, Fopurnier J, Soussi T. Prognostic significance of circulating p53 antibodies in patients undergoing surgery for locoregional breast cancer. Lancet 1995; 345: 621-2.
62. erbB4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci USA 1993; 90: 1746-50.
63. Quesnel B, Preudhomme C, Fournier J, Fenaux P, Peyrat JP. MDM2 gene amplification in human breast cancer. Eur J Cancer 1994; 30: 982-4.
64. Rodriguez E, Sreekantaiah C, Chaganti RSK. Genetic changes in epithelial solid neoplasia. Cancer Res 1994; 54: 3398-406.
65. Saint-Ruf C, Gerbault-Seureau M, Viega-Pequignot E, Zafrani B, Malfoy B, Dutrillaux B. Recurrent homogeneously staining regions in 8p1 in breast cancer and lack of amplification of POLB, LHRH, and PLAT genes. Cancer Genet Cytogenet 1991; 52: 27-36.
66. Schuuring E, Verhoeven E, van Tinteren H, Peterse JL, Nunnik B, Thunnissen FBJM, Devilee P, Cornelisse CJ, van de Vijver MJ, Mooi WJ, Michalides RJAM. Amplification of genes within the chromosome 11q13 region is indicative of poor prognosis in patients with operable breast cancer. Cancer Res 1992; 52: 5229-34.
67. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, Di Fronzo G, Rilke F, Veronesi U. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 1994; 86: 499-504.
68. Slamon DJ, Clark GM, Wong SG, Levin WS, Ullrich A, McGure WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-82.
69. Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral protein: activation, costimulation and death. Cell 1994; 76: 959-62.
70. 27/Kipl mutation found in breast cancer. Cancer Res 1996; 56: 2400-4.
71. Stewart T, Pattengale PK, Leder P. Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MMTV/myc fusion genes. Cell 1984; 38: 627-37.
72. Takira KI, Sato T, Miyagi M, Watatani M, Akiyama F, Sakamoro G, Kasumi F, Abe R, Nakamura Y. Correlation of loss of alleles on the short arms of chromosomes 11 and 17 with metastasis of primary breast cancer to lymph nodes. Cancer Res 1992; 52: 3914-7.
73. Tanner M, Tirkkonen M, Kallioniemi A, Holli K, Collins C, Kowbel D, Gray J, Kallioniemi O, Isola J. Amplification of chromosomal region 20q13 in invasive breast cancer: prognostic implications. Clin Cancer Res 1995; 1: 1455-61.
74. Teixeira C, Reed J, Pratt M. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells. Cancer Res 1995; 55: 3902-7.
75. Tlsty TD, White A, Sanchez J. Suppression of gene amplification in human cell hybrids. Science 1992; 255: 1425-7.
76. Van de Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O. Nusse R. NEU-protein overexpression in breast cancer; association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 1988; 319: 1239-45.
77. Walker GJ, Palmer JM, Walters MK, Hayward NK. A genetic model of melanoma tumorigenesis based on allelic losses. Genes Chromosom Cancer 1995; 12: 134-41.
78. Wang NP, To H, Lee WH, Lee EYHP. Tumor suppressor activity of RB and p53 genes in human breast carcinoma cells. Oncogene 1993; 8: 279-88.
79. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 1994; 369: 669-71.
80. Weinstat-Saslow D, Merino M, Manrow R, Lawrence J, Bluth R, Wittenbel K, Simpson J, Page D, Steeg P. Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. Nature Med 1995; 1: 1257-60.
81. Winqvist R, Hampton G, Mannermaa A, Blanco G, Alavaikko M, Kiviniemi H, Taskinen P, Evans G, Wright F, Newsham I, Cavenee W. Loss of heterozygosity for chromosome 11 in primary human breast tumors is associated with poor survival after metastasis. Cancer Res 1996; 55: 2660-4.
82. Wooster R, Cleton-Jansen AM, Collins N, Mangions J, Cornelis RS, Cooper CS, Gusterson BA, Ponder BAJ, Von Deimling A, Weistler OD, Cornelisse CJ, Devilee P, Stratton MR. Instability of short tandem repeats (microsatellites) in human cancers. Nature Genet 1994; 6: 152-6.
83. Yamamoto Y, Toi M, Kondo S, Matsumoto T, Suzuki H, Kitamura M, Tsuruta K, Taniguchi T, Okamoto A, Mori T, Yoshida M, Ikeda T, Tominaga T. Concentrations of vascular endothelial growth factor in the sera of normal controls and cancer patients. Clin Cancer Res 1996; 2: 821-6.
84. Yoshiji H, Gomez D, Shibuya M, Thorgeirsson U. Expression of vascular endothelial growth factor its receptor and other angiogenic factors in human breast cancer. Cancer Res 1996; 56: 2013-6.
85. INK4c in tumor-derived cell lines and primary tumors. Oncogene 1996; 12: 451-5.